Request Demo


Read more from our thought leaders.

2 min read

Why I joined Medable: Dark arts and shining lights!

By Gillian Livock on Oct 20, 2020 6:11:17 PM

Way back in the day, I remember a world when only paper CRFs existed and the transformation to EDC rapidly changed the way we managed trials.  Fast forward over 20 years and we are now experiencing another paradigm shift, moving from focusing on the site to putting the patient at the center of everything we do and leveraging digital technologies to remove the burden of participating in research.

Being part of a team, culture and organisation that drives innovation, bringing flexibility and choices to our industry, makes the weeks go fast! Never have I been so excited to explore each new day and see how we can help our sponsors and partners make a difference to their digital strategies. Bringing research to patients and the chance to deliver effective therapies faster to patients is a passion that everyone at Medable lives by.

Now the next exciting opportunity is how do we take these advancements in technology and acquisition of data to identify digital therapeutics. The interoperability of the Medable platform means that outside data streams can enrich our existing modules to bring more insights. We don't know what we don't know. However, applying data science and machine learning to these data insights can identify trends and outliers which can help us look at patient populations differently and in more depth. 

Imagine a day when patients can be digitally assessed to match the best treatment that they will respond to based on how their individual physiology is impacted by a disease.  We have made exciting advances in treating patients and finding new ways to tackle life threatening illness, however in many cases patients are still treated based on the overall response of how others have progressed and responded. I am excited to be part of a company who can contribute significantly to this next wave of advancement in finding digital therapeutics for patients. 

Certainly for me, technology is part of how I function in my everyday life. My parents are now experts in online shopping and accessing their grandchildren through technology….arguably the pandemic has provided the biggest learning opportunity of our lifetime!  Where technology may once have been seen as a “dark art” by certain generations, it is now their way of life and opportunity to connect to a world which has become smaller. Medable is helping patients, sites and study teams stay connected in times of darkness and shining a light to deliver a new way of conducting research.

Medable is rapidly growing and we’re looking for passionate teammates to join our mission across every part of our company. If you’re interested in joining us, please visit

Topics: decentralized trials careers DCT
3 min read

Why I Joined Medable: Putting Patients (and Clinicians) at the Center of the Trial Experience

By David Swanger on Oct 9, 2020 1:36:26 PM

Li_Tile (74)

Clinical Development rapidly advanced this past decade. New endpoints and measures covering genomics and devices emerged. New design methodologies like adaptive trials and basket trials gained acceptance. And new advances in clinical operations in areas like risk based monitoring improved safety and efficacy.

In spite of substantial progress, several challenges remain. Today patient access and patient retention persist as the costliest and most time consuming challenges our industry faces. We’re all familiar with the statistics and persistent challenges they underscore. A relatively recent analysis of data, “Terminated Trials in the Results Database: Evaluation of Availability of Primary Outcome Data and Reasons for Termination” underscores the challenges surrounding patient participation in clinical trials:

The analysis finds that of the studies that were terminated in the database, 68% were done so due to reasons other than data accrual, and of that cohort, 57% were terminated due to an insufficient rate of accrual.

Patient enrollment and retention continue to challenge our industry, and that was prior to our global pandemic. And with precision medicine leading to ever narrower treatments and patient populations, these twin challenges will likely persist.

Improving on these challenges will require a rethink across the clinical development continuum that prioritizes patient experience at every step in the process. Ultimately the sponsors and CRO's that prioritize the patient's experience throughout the clinical development lifecycle will benefit from faster FPI to LPO cycles and a higher proportion of studies with sufficient data accrual to complete the study.

What will putting the patient at the center of the clindev experience look like?

If you ask me, it looks a lot like Medable's Patient, Site, and Sponsor apps.

Each has been developed in close partnership with some of the leading patient advocates, doctors, researchers, and clinicians across clinical development. And with every standardized offering or workflow, Medable has stopped to ask the question, "Does this enhance or hinder the patient (and clinician) experience?"

The result is a fundamentally new approach to clinical development, one that utilizes best practices from Medable’s deep learnings in hybrid and decentralized clinical trials (DCT's). These learnings are then complemented by a commitment to delivering the same consumer-grade experience that delights patients and clinicians when they use their favorite apps like Netflix or AirBnB.

In practice this means that we strive to allow sponsors and CRO’s to right-size their journey to DCT’s by offering a Readiness Framework that clearly shows the progression from light-weight TeleVisit and TeleConsent capabilities to capturing digital endpoints via COA’s, PRO’s, and other forms of digital source data.



At Medable we recognize that each study is unique. Each covers a different treatment and operates in a unique combination of phase, therapeutic area, regulatory environment, and much more. That means that every Decentralized Clinical Trial (DCT) must fit the unique needs of the patients, investigators, clinical, and regulatory professionals and ensure clinical trials continue to deliver the quality our patients deserve and regulators require.

That’s why I’m so excited to be part of a team of diverse clinical leaders who have the experience, perspective, and passion to help the clinical development process to evolve in a meaningfully positive way. And it starts with our CEO Michelle Longmire, a true visionary who leads by example and is steadfastly committed to ensuring we succeed as a team.

Getting the chance to shape a fundamentally new approach to something as important as drug discovery and commercialization is quite rare. And for that I am grateful to be part of an amazing company that is laser focused on solving the twin challenges of patient access and recruitment. It’s why I joined Medable.

If you'd like to join Medable and help shape the future of the growing DCT movement, we invite you to join us. We are hiring (or will be soon) in just about every department and every geography. I’m looking for strong marketers in product marketing, demand gen/growth, brand/creative, and more. Feel free to apply at

Topics: careers
2 min read

Why Medable: CEO Manifesto

By Michelle Longmire on Sep 21, 2020 1:54:09 PM


Untitled design (38)

Mission matters

Throughout my career, I have had the opportunity to work as a scientist, physician, and CEO. I have enjoyed every job I have ever had, whether it was researching epigenetics of disease or caring for patients with skin disease. Yet, prior to Medable, I had not felt that “I was born to do this.” 

Founding and building Medable is something that I truly feel like I was born to do. I say this not because it is easy or that I do not have many areas of growth as a CEO, I say this because of the impact of our mission - enabling effective therapies to reach patients faster through better clinical trials means less suffering and better health, worldwide.

Our team deeply believes that as we execute on our mission, we will enable better treatment of the more than 7,000 uncured and sub optimally treated diseases. At Medable, our team lives to deliver on our mission and we strive everyday to execute towards this goal. 

Medable team

Team matters

Among the many things I have learned in building a company, is that the team is everything. At Medable, our motto is to be the strongest teammate and fiercest opponent. Rasmus Hogreffe, VP of Clinical Trial Innovation recently said to me, “Michelle, while other companies can replicate software, no one can replicate people, our team is what makes us Medable.”  At Medable, we empower one another to be the best on the field in our respective positions. It is through this team philosophy that we achieve synergy and outcomes beyond the capability of any single individual and often surprise even ourselves in what we can accomplish.

Impact matters

The fascinating thing about building a company, is that you are truly building something. Every person impacts the current and future form of the company and the smaller the company, the bigger the impact. From project managers to sales people and engineers, together we are all building Medable. This means that every single person is shaping and influencing our current and future state. It is incredibly exciting to see Medable get stronger as we develop and grow and how each team member truly shapes the future of the company with the unique skills, perspective, experiences, and passion that they bring to our team. 

medable team

Join us if ...

If you love learning, are humble but confident, empathetic yet unrelenting in the pursuit of goals, are inspired to be the best teammate and fiercest opponent - and, most importantly - are dedicated to the mission of getting effective therapies to patients faster, Medable wants you.

Visit our careers page. 

Topics: medable careers